These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 7733623

  • 1. Quantitative description of morphologic changes effected by antileukemic agents in L1210 leukemia cells.
    Iwasaki H, Liu YP, Nojyo Y, Ueda T, Nakamura T.
    Anticancer Res; 1995; 15(1):133-9. PubMed ID: 7733623
    [Abstract] [Full Text] [Related]

  • 2. Morphologic differences in leukemic cells (L1210) exposed to 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Iwasaki H, Aoyama H, Ueda T, Uchida M, Nakamura T.
    Anticancer Res; 1992; 12(3):941-7. PubMed ID: 1622152
    [Abstract] [Full Text] [Related]

  • 3. Cell proliferation kinetics and drug sensitivity of exponential and stationary populations of cultured L1210 cells.
    Bhuyan BK, Fraser TJ, Day KJ.
    Cancer Res; 1977 Apr; 37(4):1057-63. PubMed ID: 139202
    [Abstract] [Full Text] [Related]

  • 4. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells.
    Breier A, Drobná Z, Barancík M.
    Neoplasma; 1998 Apr; 45(4):248-53. PubMed ID: 9890669
    [Abstract] [Full Text] [Related]

  • 5. [Biochemistry of antileukemic drugs].
    Bollag W.
    Schweiz Med Wochenschr; 1970 Feb 14; 100(7):310-4. PubMed ID: 4908606
    [No Abstract] [Full Text] [Related]

  • 6. Electronic volume analysis of L1210 chemotherapy.
    Zucker RM, Helfman D.
    Cancer Res; 1976 Dec 14; 36(12):4434-8. PubMed ID: 1000492
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative kinetics of poly(6-thioinosinic acid) and 6-mercaptopurine treated L1210 cells.
    Tomasovic SP, Higashikubo R, Cohen AM, Broom AD.
    Cytometry; 1982 Jul 14; 3(1):48-54. PubMed ID: 6889485
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antitumor activity of novel octalactin A analogs in murine leukemia cells in vitro.
    Perchellet JP, Perchellet EM, Newell SW, Freeman JA, Ladesich JB, Jeong Y, Sato N, Buszek K.
    Anticancer Res; 1998 Jul 14; 18(1A):97-106. PubMed ID: 9568062
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Action mechanisms of zinostatin stimalamer (YM881)].
    Tanaka S, Numasaki Y, Maeda H.
    Gan To Kagaku Ryoho; 1991 Oct 14; 18(13):2295-300. PubMed ID: 1834022
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo antileukemic effect of novel dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine.
    Rauko P, Novotny L, Mego M, Saiko P, Schott H, Szekeres T.
    Neoplasma; 2007 Oct 14; 54(1):68-74. PubMed ID: 17203895
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S, Goto N, Nakamura T, Ueda T.
    Cancer Res; 1999 Jun 01; 59(11):2629-34. PubMed ID: 10363985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.